Japanese Prime Minister Fumio Kishida recently announced that the country may consider authorizing Shionogi’s (TYO:4507) S-217622 coronavirus-3C-like-proteinase inhibitor based on strong data from a Phase 2a study. In that study, recipients of S-217622 had significant improvement in viral load reduction compared to those who received a placebo. In addition, those who received the experimental drug…